Giuseppe A. Palumbo - Concepedia

Author

Giuseppe A. Palumbo

Also Known As

G A Palumbo, G PALUMBO, G Palumbo, G. A. Palumbo, G. PALUMBO, G. Palumbo, G.A. Palumbo, GA Palumbo, GIUSEPPE Albero Palumbo, GIUSEPPE PALUMBO JR

437

Publications

7.6K

Citations

H-Index

202

Concepts

All Affiliations

University of Catania Sapienza University of Rome Istituti di Ricovero e Cura a Carattere Scientifico St. Eugenio Hospital Tecnologie Avanzate (Italy)

About

Giuseppe A. Palumbo is an author at University of Catania specializing in medicine, hematology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	61	3.5K
2	Health Sciences	13	15	455
3	Engineering	1	1	18
4	Natural Sciences	1	1	27
5	Nursing	1	1	21

Giuseppe A. Palumbo

127

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Michèle Cavo, Francesca Gay, Meral Beksaç, The Lancet Haematology Hematological MalignancyTransplantationMarrow TransplantationMedicineStem Cell Transplantation	2020	377
Mutation and Haplotype Studies of Familial Mediterranean Fever Reveal New Ancestral Relationships and Evidence for a High Carrier Frequency with Reduced Penetrance in the Ashkenazi Jewish Population Ivona Aksentijevich, Yelizaveta Torosyan, Jonathan Samuels, The American Journal of Human Genetics Haplotype StudiesDisease SusceptibilityGenetic DisorderMedicineGenetics	1999	293
M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro Marzia Leidi, Elisa Gotti, Luca Bologna, The Journal of Immunology ImmunologyCell DeathPathologyImmunologic MechanismImmunotherapy	2009	260
Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Francesco Di Raimondo, MP Azzaro, Giuseppe A. Palumbo, PubMed	2000	169
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial Esther Natalie Olíva, Caterina Alati, Valeria Santini, The Lancet Haematology Eltrombopag Versus PlaceboThrombosisThrombopoiesisHematological MalignancySuperiority Trial	2017	159
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio, Cancer	2019	144
CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia Giuseppe A. Palumbo, Nunziatina Laura Parrinello, Giovannella Fargione, Leukemia Research Hematological MalignancyLymphoid NeoplasiaMantle Cell LymphomaMedicineCd200 Expression	2009	139
Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Restoration of Age-Associated Decline of Thymus Weight, Thymic LHRH Receptors, and Thymocyte Proliferative Capacity Bianca Marchetti, Vincenzo Guarcello, Maria C. Morale, Endocrinology Growth HormoneAgingAllergyEndocrine MechanismLongevity	1989	127
Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial Sara Galimberti, Stefano Luminari, Elena Ciabatti, Clinical Cancer Research Hematological MalignancyPcr StatusMrd NegativityLymphoid NeoplasiaMedicine	2014	112
Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts Haifa Kathrin Al‐Ali, Martin Grießhammer, Lynda Foltz, British Journal of Haematology	2020	105

Page 1